We are tackling the biggest medical challenges of our generation.

 

The breadth and depth of our pipeline demonstrates the power of the ConVERGE® platform. All pipeline programs have been discovered and developed on our proprietary platform.

Good treatments have long been developed for diseases with well-understood biology and predictive disease models. All that remains are diseases with complex biology, where animal and cell models do not predict whether drugs work. Accelerating the pace of bringing effective, new medicines to these patients is one of the greatest opportunities for humanity.

The ConVERGE® platform addresses diseases where biology is the bottleneck. Our programs target therapeutic areas where:

  • Multi-factorial components (genetics, environment, and time) intersect in complex ways to culminate in overt disease
  • Animal or cell models do not predict human efficacy
  • There is high unmet need, no disease-modifying therapies, or significant shortcomings with existing treatment paradigms
Cover-01 4-3.png

*Learn about our clinical trial at ClinicalTrials.gov.

Early
Discovery
Late
Discovery
Preclinical
Phase 1
Proof of Concept
Verge Pipeline Programs
ALS PIKfyveVisit ClinicalTrials.gov.
Parkinson's Disease
Schizophrenia
Neurodegenerative Diseases
Psoriasis
Atopic Dermatitis
Crohn's Disease
Ulcerative Colitis
Partnered Programs
ALS
Neurodegenerative Diseases

*Learn about our clinical trial at ClinicalTrials.gov.

From novel target to clinical candidate on one platform.

 

We are the first AI-enabled drug discovery company to discover a novel target and develop it into a clinical candidate entirely in-house. Most AI-enabled companies make new drugs against old targets, or old drugs against new targets. We discovered a new target from our platform and developed our own proprietary clinical compound internally "soup-to-nuts.”

 
 
SVG file icon
SVG file icon
SVG file icon
SVG file icon
 

AI enabled new target and drug discovery is transforming how we find therapeutics.


 

Cover-01 4.png